gastroenterologyadvisor2h
Inavolisib + Palbociclib-Fulvestrant Improves Survival in Advanced Breast Cancer
Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, ...
Cancer Therapy Advisor19h
Camizestrant Outperforms Fulvestrant in ER+, HER2- Breast Cancer
Camizestrant significantly improved progression-free survival (PFS) compared to fulvestrant in patients with estrogen receptor (ER)-positive, HER2-negative breast cancer ... The objective response ...
News Medical2d
Cleveland Clinic presents new findings on triple-negative breast cancer vaccine
Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
T-Net3d
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, ...
Too Old to Operate5d
Molecular Signatures and pCR Outcomes in HR+/HER2- Early Breast Cancer
The following is a summary of “Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage ...